Evidence map›Paper›PMID 40208039›Full record

ArticleInfection and immunity2025

Immunogenicity and preclinical efficacy characterization of ShecVax, a combined vaccine against

Siqi Li, Ipshita Upadhyay, Hyesuk Seo, Sai S R Vakamalla, Aashwina Madhwal, David A Sack, Weiping Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Recent progress in enterotoxigenicInfection and immunity · 2025
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Siqi LiDepartment of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
Ipshita UpadhyayDepartment of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
Hyesuk SeoDepartment of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
Sai S R VakamallaDepartment of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
Aashwina MadhwalDepartment of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
David A SackDepartment of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
Weiping ZhangDepartment of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.ORCID 0000-0002-3723-2257

Funding

Development of MecVax, a Cross Protective Subunit Vaccine for ETECR01AI177144 · NIAID · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI WEIPING ZHANG · 2023 to 2026
$4.6M
A cross protective multivalent vaccine for Shigella and ETECR01AI175214 · NIAID · JOHNS HOPKINS UNIVERSITY · PI DAVID A SACK · 2023 to 2026
$3.0M
A broadly protective subunit vaccine against enterotoxigenic Escherichia coli (ETEC) associateddiarrheaR01AI121067 · NIAID · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI ZHANG, WEIPING · 2016 to 2020
$2.0M
National Institute of Allergy and Infectious Diseases R01AI121067National Institute of Allergy and Infectious Diseases R01AI175214National Institute of Allergy and Infectious Diseases R01AI177144NIAID NIH HHS R01 AI121067NIAID NIH HHS R01 AI175214NIAID NIH HHS R01 AI177144
6 · The paper itself

Abstract

No licensed vaccines are available for the largely antibiotic-resistant

Indexed as

Dysentery, BacillaryEnterotoxigenic Escherichia coliEscherichia coli InfectionsEscherichia coli VaccinesImmunogenicity, VaccineShigellaShigella VaccinesAnimalsAntibodies, BacterialAntigens, BacterialDiarrheaFemaleMiceMice, Inbred BALB CRabbitsVaccines, CombinedAntibodies, BacterialAntigens, BacterialEscherichia coli VaccinesShigella VaccinesVaccines, CombinedVirulence Factorscombined vaccinediarrheaenterotoxigenic Escherichia coli (ETEC)EPImultiepitope fusion antigen (MEFA)Shigellavaccinology platform

Identifiers

PMID40208039
PMCPMC12150686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.